0.0750USD-14.77%Mkt Cap: 2.18M USDP/E: 0.06Last update: 2026-05-26
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It develop…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap2.18M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.28M USD
Revenue/Share—
Last Price0.0750 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4268971045
Valuation
P/E (Trailing)0.06
P/E (Forward)-0.01
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.08
EPS (TTM)1.20
EPS (Forward)-11.43
52W Range
0.033019% of range0.2500
52W High0.2500 USD
52W Low0.0330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-310.32%
ROA-269.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.27M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio—
Quick Ratio—
Book Value/Sh0.0840 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 3, 2019
Splits
Last Split1:50
Split DateMar 18, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.29.12M
Float—
Insiders25.76%
Institutions0.02%
Short Interest
Short Ratio0.1d
Short % Float4.10%
Short % Out.4.10%
Shares Short448.18K
Short (prev mo.)199.81K
Technical
SMA 500.0571 (+31.3%)
SMA 2000.0605 (+23.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)31.37K
Avg Vol (10d)37.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—